Kazia Therapeutics Ltd Stock Net Income
| KZIA Stock | USD 6.40 0.06 0.93% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Kazia Therapeutics' long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -20.7 M | -21.7 M | |
| Net Loss | -20.7 M | -21.7 M | |
| Net Loss | -18.4 M | -19.3 M | |
| Net Loss | (50.25) | (52.76) | |
| Net Income Per E B T | 0.89 | 0.70 |
Kazia | Net Income | Build AI portfolio with Kazia Stock |
Kazia Therapeutics Ltd Company Net Income Analysis
Kazia Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Kazia Therapeutics Net Income | (20.7 M) |
Most of Kazia Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kazia Therapeutics Ltd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kazia Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kazia Therapeutics is extremely important. It helps to project a fair market value of Kazia Stock properly, considering its historical fundamentals such as Net Income. Since Kazia Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kazia Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kazia Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kazia Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kazia Therapeutics Ltd reported net income of (20.7 Million). This is 106.07% lower than that of the Biotechnology sector and 129.55% lower than that of the Health Care industry. The net income for all United States stocks is 103.63% higher than that of the company.
Kazia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kazia Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kazia Therapeutics could also be used in its relative valuation, which is a method of valuing Kazia Therapeutics by comparing valuation metrics of similar companies.Kazia Therapeutics is currently under evaluation in net income category among its peers.
Kazia Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kazia Therapeutics from analyzing Kazia Therapeutics' financial statements. These drivers represent accounts that assess Kazia Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kazia Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 37.4M | 154.7M | 32.1M | 7.8M | 9.0M | 8.5M | |
| Enterprise Value | 28.7M | 127.1M | 28.6M | 6.8M | 7.8M | 7.4M |
Kazia Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kazia Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kazia Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Kazia Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Kazia Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kazia Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kazia Therapeutics' value.| Shares | Citigroup Inc | 2025-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 0.0 | Jpmorgan Chase & Co | 2025-03-31 | 0.0 | Dauntless Investment Group, Llc | 2025-06-30 | 115.8 K | Barclays Plc | 2025-06-30 | 24 K | Ubs Group Ag | 2025-06-30 | 3 K | Rhumbline Advisers | 2025-06-30 | 591 | Gamma Investing Llc | 2025-06-30 | 265 | Srs Capital Advisors Inc | 2025-06-30 | 200 | Sbi Securities Co Ltd | 2025-06-30 | 100.0 | Mccormack Advisors International | 2025-06-30 | 52.0 |
Kazia Fundamentals
| Return On Equity | -38.92 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (2.68) % | ||||
| Current Valuation | 83.17 M | ||||
| Shares Outstanding | 11.34 M | ||||
| Shares Owned By Insiders | 1.38 % | ||||
| Shares Owned By Institutions | 1.74 % | ||||
| Number Of Shares Shorted | 40.5 K | ||||
| Price To Earning | (5.35) X | ||||
| Price To Book | 3.09 X | ||||
| Price To Sales | 38.30 X | ||||
| Revenue | 42 K | ||||
| Gross Profit | 1.83 M | ||||
| EBITDA | (13.28 M) | ||||
| Net Income | (20.7 M) | ||||
| Cash And Equivalents | 7.36 M | ||||
| Cash Per Share | 0.49 X | ||||
| Total Debt | 396 K | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 1.62 X | ||||
| Book Value Per Share | (3.44) X | ||||
| Cash Flow From Operations | (13.28 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (10.34) X | ||||
| Target Price | 19.17 | ||||
| Beta | 1.68 | ||||
| Market Capitalization | 70.06 M | ||||
| Total Asset | 6.06 M | ||||
| Retained Earnings | (134.83 M) | ||||
| Working Capital | (9.12 M) | ||||
| Current Asset | 35.14 M | ||||
| Current Liabilities | 5.49 M | ||||
| Net Asset | 6.06 M |
About Kazia Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kazia Therapeutics Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kazia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kazia Therapeutics Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kazia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kazia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kazia Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kazia Therapeutics Ltd Stock:Check out Kazia Therapeutics Piotroski F Score and Kazia Therapeutics Altman Z Score analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kazia Therapeutics. If investors know Kazia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kazia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.34) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
The market value of Kazia Therapeutics is measured differently than its book value, which is the value of Kazia that is recorded on the company's balance sheet. Investors also form their own opinion of Kazia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kazia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kazia Therapeutics' market value can be influenced by many factors that don't directly affect Kazia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kazia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kazia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kazia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.